An Open-Label Proof of Concept Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestationsof Antiphospholipid Syndrome

Project: Other project

StatusFinished
Effective start/end date2/4/1411/17/17

Funding

  • Quintiles, Inc.: $32,644.63